Objectives: Patients with myasthenia gravis (MG) are subgrouped as acetylcholine receptor (AChR)positive, muscle-specific kinase (MuSK)-positive, and AChR/MuSK-negative MG (or double negative [DN]) on the basis of autoantibody assay. We investigated the relationships between autoantibody specificity, main clinical features, and outcome of the disease, in particular the occurrence of complete stable remission (CSR), by means of a retrospective study on a cohort of 677 Italian patients with MG.
The prognosis of myasthenia gravis (MG) has not been properly investigated, mainly due to lack of national registries, shortness of follow-up, and heterogeneous definition of outcome measures. In 1991, we reported a multicenter study involving 844 Italian patients focusing on the chance of achieving complete stable remission (CSR): the cumulative probability of achieving CSR was 21% by 10 years. 1 The achievement of CSR correlated with younger age at onset, clinical stage at onset and at maximal worsening, and shorter disease duration at diagnosis. Anti-acetylcholine receptor (AChR) antibodies (Ab), the immunologic hallmark of the disease, are detected in about 85% of patients with generalized MG. MG without anti-AChR Ab has been defined as seronegative MG. 2 A proportion of seronegative MG sera contain antibodies to muscle-specific kinase (MuSK). 3, 4 Therefore, patients with seronegative MG can now be divided into MuSK-positive and AChR/MuSK-negative (or double negative [DN] ). Clinical features of MG seem to be more severe in MuSK-positive patients, 5, 6 with predominant involvement of ocular and bulbar muscles and relative sparing of the limbs.
In the present study, we investigated the relationships between autoantibody specificity (AChR-positive, MuSK-positive, and DN), clinical features, and the chance of achieving CSR in a cohort of 677 Italian patients with MG. METHODS Patients. This is a retrospective cohort study on 975 patients with MG followed up at our institute from January 1980 to December 2009; 677 patients fulfilled the inclusion criteria: at least 1 year of clinical follow-up and availability of anti-AChR and anti-MuSK antibody assay. The diagnosis of MG was based on the association of fluctuating muscle weakness and fatigability together with one or more of the following criteria: decrement of more than 10% in the amplitude of the compound muscle action potential on repetitive nerve stimulation, increased jitter on single-fiber EMG, positive response to acetylcholinesterase inhibitors, and positive AChR or MuSK antibody assay. In DN patients, the diagnosis of MG was confirmed by neurophysiologic investigations.
Standard protocol approvals, registrations, and patient consents. The study was approved by the Institute Clinical Trial Center; written informed consent was obtained by the patients included in the study.
Autoantibody assay.
Anti-AChR antibodies were tested in all patients on serum samples collected at the time of diagnosis. All sera with a negative value (,0.5 nM) were tested for anti-MuSK antibodies. Autoantibodies were measured by radioimmunoassay according to manufacturer's instructions (RSR Limited, Cardiff, UK).
Clinical evaluation. The main clinical features of the disease were recorded taking into account the involvement of different muscular districts during the entire follow-up (in particular, eyelid ptosis, ophthalmoparesis, dysphagia, nasal voice, respiratory symptoms, and generalized weakness-neck, upper, and lower limbs). The number of respiratory crises with need for assisted ventilation was also recorded as well as treatment with plasma exchange (PE) and intravenous immunoglobulin (IVIg). The mean 6 SD follow-up time was 5.8 6 4.4 years (range 1-29.5 years). Patients were grouped according to the 3 antibody specificities as follows: AChR-positive, MuSK-positive, and AChR-and MuSK-negative (DN).
Clinical staging and outcome definition. Clinical stage was graded at the onset of the disease, at maximal worsening, and at the end of the clinical follow-up. 7 The following categories were considered: ocular MG; generalized MG (involvement of limb and trunk muscles); bulbar MG (generalized MG with bulbar muscle involvement); respiratory MG (generalized MG or bulbar MG with respiratory compromise); pharmacologic remission (PR); CSR (no symptoms or signs of MG for at least 1 year without any pharmacologic treatment); died of MG.
The MG postintervention status (PIS) was reported according to the Myasthenia Gravis Foundation of America (MGFA) recommendations. 8 The following categories were considered: CSR, PR, minimal manifestations, improved, unchanged, worse, died of MG.
Thymus pathology. Thymus histology was available for all patients undergoing thymectomy (n 5 441). The following categories were considered: involuted thymus, thymic hyperplasia, and thymoma; diagnosis of thymoma was performed according to the World Health Organization classification. 9 Statistical analyses. Differences in baseline characteristics of AChR-positive, MuSK-positive, and DN groups were evaluated using x 2 or Fisher exact test. Kaplan-Meier analysis was used to investigate the chance of achieving CSR in the 3 MG groups and the log-rank test was used to calculate the difference between the survival curves. Cox proportional hazard regression analysis was then used to assess the effect of baseline characteristics and antibody specificity on CSR, after having verified the hypothesis of proportional hazards, which was tested using the Schoenfeld residuals method. A stratified Cox analysis was carried out for those variables that did not satisfy the proportional hazard assumption. A multivariate logistic model was used to study the potential association between antibody type and disease severity (i.e., bulbar dysfunction).
Data analysis was carried out using Statview 5 for Macintosh (Abacus Concepts, Berkeley, CA), GraphPad Prism version 4.0 for Macintosh (GraphPad Software Incorporated, La Jolla, CA), and Stata 11.0 (StataCorp, College Station, TX).
RESULTS
The study group consisted of 677 patients with MG, including 517 AChR-positive (76%), 55 MuSK-positive (8%), and 105 DN (16%) patients. The main clinical features of the patients are reported in table 1.
Gender frequencies were statistically different in our series ( p 5 0.016), with an F:M ratio of 5.1:1 for MuSK-positive patients. Mean age at onset was similar in the 3 groups. MG onset occurred before 12 years of age in 23 patients (3.4%; 1 MuSK-positive and 22 AChR-positive). Disease duration was significantly different ( p 5 0.012).
The distribution of MG clinical stages at onset was different among the 3 groups ( p , 0.001). Indeed, 60.1% of MuSK-positive patients showed bulbar dysfunction at onset compared with 35.2% of AChR-positive patients and 23.8% of DN patients. On the contrary, only 9.1% of MuSK-positive patients were graded as generalized at onset.
The observed distribution of clinical stages was more evident at maximal worsening: 83.6% of MuSK-positive patients were graded as bulbar compared with 58.6% in the AChR-positive and 43.8% in the DN groups ( p , 0.001); respiratory insufficiency was more frequently observed in the MuSK-positive group (10.9%).
The clinical stage at last observation and the MGFA PIS are reported in table 1. The occurrence of CSR was observed in 140/677 (20.7%) patients with MG: only 2/55 (3.6%) MuSK-positive patients reached CSR compared with 115/517 (22.2%) in the AChR-positive and 23/105 (21.9%) in the DN group ( p 5 0.005, Fisher exact test for CSR vs cumulated non-CSR outcomes, see table 1). Eleven CSR (47.8%) were recorded in the 23 pediatric patients: one of them was MuSKpositive. The occurrence of CSR in AChR-positive patients with disease onset after 12 years of age was 21.2% (n 5 105 CSR) in the 495 AChR-positive adults, a percentage similar to that found in the whole group of 517 AChR-positive subjects (22.2%).
The number of patients who showed bulbar symptoms at last observation was 16/55 (29.1%) in the MuSKpositive group, vs only 7/105 (6.7%) DN and 30/517 (5.8%) AChR-positive patients. Occurrence of CSR compared with positive and negative PIS outcomes was again significant (p 5 0.003, Fisher exact test, see table 1).
Histologic findings of thymic tissue were available for all 441 thymectomized patients. Twenty-five MuSK-positive patients were thymectomized: no thymomas were found; 10 showed abnormal histologic findings: hyperplasia in 6 (5 typical hyperplasia and 1 thymitis, 24%) compared with 46.4% in AChR-positive and 46.2% in DN patients (p , 0.001); 4 patients showed signs of focal hyperplasia within fatty thymuses and were considered as involuted. Histologic findings of these 10 MuSK-positive patients are provided in table e-4 and figure e-1 on the Neurology ® Web site at www.neurology.org.
The involvement of different muscle groups during the whole patient history in AChR-positive, MuSK-positive, and DN MG is reported in table e-1. The incidence of nasal speech and dysphagia varied in the 3 groups, being recorded most frequently in patients with MuSK-positive MG (up to 90%) compared with AChR-positive (60%) and DN patients, in whom bulbar involvement was less frequent (up to 37%). On the contrary, generalized muscle weakness and fatigability, recorded in more than 90% of both AChR-positive and DN patients, occurred less frequently in MuSK-positive MG. Respiratory crises were recorded in 10.9% of MuSK-positive patients, 6.8% of AChR-positive patients, and in only 1 DN patient.
The involvement of bulbar muscles was again more frequently observed at the last observation when 29% of MuSK-positive patients were graded as bulbar compared with 5.8% in AChR-positive and 6.8% in DN patients.
The response to immunomodulation with PE or IVIg is reported in table e-1. A favorable response to both immunomodulatory treatments was found in the 3 groups without differences among them. It is worth noting that 95.8% of MuSK-positive patients submitted to PE improved with this procedure.
The cumulative probability of achieving CSR in the whole sample of 677 patients with MG included in the study, according to sex, age at onset, clinical stage at onset and at maximal worsening, autoantibody specificity, and thymus histology (available for the 441 patients with MG undergoing thymectomy), was calculated by the Kaplan-Meier method. Among these variables, age at onset ( p 5 0.0004), clinical stage at maximal worsening ( p 5 0.0054), autoantibody specificity ( p 5 0.0382), and histologic findings ( p 5 0.0030) were associated with the chance of achieving CSR (figure 1).
The cumulative probability of achieving CSR was also studied in the 3 subgroups: AChR-positive (n 5 517), MuSK-positive (n 5 55), and DN patients (n 5 105). Results are reported in figure 2 ; the graphs regarding MuSK-positive patients are not shown since only 2 CSR occurred (table 1). The 2 MuSK-positive patients who reached CSR were female, with disease onset before the age of 40 years, and with histologic finding of Continued involuted thymus; they were both treated only with corticosteroids. The analysis showed that in AChR-positive patients the variables age at onset (p 5 0.0059), clinical stage at maximal worsening (p , 0.0001), and histologic findings (p 5 0.0050) were associated with the chance of achieving CSR (figure 2), while in the DN group the chance of achieving CSR was of borderline significance (p 5 0.0535) with regard to the age at onset only ( figure 3 ). Cox proportional hazard regression analysis was used to evaluate associations between baseline characteristics, antibody specificity, and CSR. Among the variables considered (i.e., sex, age at onset, clinical stage at onset and at maximal worsening, histologic findings, and antibody specificity), only age at onset ,40 years, clinical stage at maximal worsening, and histologic findings were significantly associated with CSR by univariate analysis (table e-2).
We then performed a multivariate analysis on the whole sample of 677 patients including sex, age at onset, and clinical stage at maximal worsening with autoantibody specificity as stratification variable since it did not satisfy the proportional hazard assumption (table 2). We found that onset before age 40 (hazard ratio [HR] 5 1.96, 95% confidence interval [CI] 1.27- 2) . Multivariate analysis performed in the subgroup of 441 thymectomized patients, including histologic findings as independent variable, showed again that clinical stage at maximal worsening was associated with CSR (table e-2).
To investigate the potential association between disease severity at maximal worsening (i.e., bulbar dysfunction, n 5 395/677 patients) and antibody type, we performed a multivariate logistic model considering sex, age at onset, and antibody type as independent variables (table e-3) . Again, MuSK-positive patients had an increased risk of showing bulbar dysfunction (odds ratio [OR] 3.80, CI 1.81-7.96) compared with AChR-positive patients, while DN patients had a reduced risk (OR 0.56, CI 0.37-0.86). Similar data were obtained considering bulbar dysfunction at onset. DISCUSSION Therapeutic strategies for MG improved considerably the course of the disease during the last 50 years. 10, 11 Treatments have been optimized, and immunomodulation with IVIg and PE has a recognized role in the management of critical conditions. However, the clinical response varies considerably, ranging from patients reaching CSR to those showing severe impairment despite prolonged immunosuppression. We still lack reliable clinical and biological markers able to predict the course of the disease and the response to treatments.
Patients with undetectable antibodies against AChR have always been of particular interest, but the clinical differences lacked an immunologic counterpart. In this regard, the discovery of anti-MuSK antibodies in "seronegative" MG represented the first example of a different pathogenetic background in the same autoimmune disease. 3, 11, 12 Such a different immunopathologic basis may be responsible for differences in clinical presentation, response to treatments, and, ultimately, final outcome.
Indeed, the presence of anti-MuSK antibodies defines a distinct clinical and immunopathologic subtype of MG, as emerged from reported clinical series, 13 and the 2 cohorts recently described. 14 The proportion of MuSK-positive patients varies in published series, likely due to the heterogeneity in the number of patients and differences in their geographic origin. Moreover, there are few reports on the comparison between AChR-positive, MuSK-positive, and DN patients. 13, 15 The availability of a large sample of patients is mandatory when investigating the clinical features and outcome of the disease.
We therefore analyzed a large population of patients with MG diagnosed and followed up at our institution by the same group of neurologists, to investigate the relationships between each autoantibody specificity (AChR-positive, MuSK-positive, and DN), clinical features, and outcome, focusing on the chance of achieving CSR.
We confirm that MuSK-positive is more severe than AChR-positive and DN MG, as shown by the high incidence of bulbar symptoms in MuSK-positive patients at onset and at maximal worsening; respiratory crises were recorded in 10.9% of our patients. Respiratory insufficiency in MuSK patients has been reported with variable frequencies. 13 It is likely that the number of patients investigated and differences in the management of critically ill patients might account for these differences. We did not observe patients with predominant involvement of the neck, shoulder, and respiratory muscles with delayed oculo-bulbar weakness. 6 Table 2 Cox multivariate analysis of complete stable remission according to clinical variables a Generalized weakness was clearly less frequent in MuSK MG compared with the other groups that were similar in terms of clinical presentation at different time points. The observation of low-affinity anti-AChR antibodies in DN MG might explain a clinical course similar to that of AChR-positive patients as well as response to PE or IVIg. 16 A positive response to immunomodulatory treatments in MuSK-positive patients is worth noting (table e-1) and particularly important in these patients due to their tendency to develop severe bulbar symptoms and respiratory crisis.
The incidence of bulbar symptoms at last observation was still 29% in patients with MuSK-positive MG, considerably higher than the other groups, indicating a less favorable response to immunosuppression in the long term. We do not think that a delay in diagnosis contributed to the severity of MuSK-positive MG in our series since the time to diagnosis was similar in the 3 groups (table 1) .
The issue of thymic abnormalities in MuSK-associated MG remains open. 17, 18 Indeed, we observed thymic hyperplasia in 6 out of 25 patients with MuSK-positive MG. Interestingly, one of these patients, already reported in detail elsewhere, showed thymitis with B-cell proliferation. 19 However, the number of thymectomized MuSKpositive patients was too low to draw any conclusion, suggesting the need for multicenter studies.
We then investigated the correlation between antibody specificity, clinical parameters, and disease outcome at the end of the follow-up, i.e., the chance of achieving CSR. Kaplan-Meier analysis showed that age at onset, clinical stage at maximal worsening, autoantibody specificity, and thymic histology were associated with the chance of achieving CSR in the whole cohort of patients with MG. Only 2 out of 55 (3.6%) MuSK-positive patients with MG achieved CSR, compared with 22.2% of AChR-positive and 21.9% of DN patients. In our series, the occurrence of CSR was much lower in MuSK-positive patients compared with that recorded in a recent cohort (12.3% CSR in AChR-positive patients and 7.3% in MuSK-positive patients); moreover, DN patients were not considered in that study. 14 Therefore, in our experience the outcome of the disease in terms of CSR is not similar between AChR-positive and MuSK-positive patients. 14 CSR was not reported in another series that included DN MG patients. 15 Multivariate analysis showed that disease onset before the age of 40 years and less severe clinical stages at maximal worsening (ocular and generalized MG) were associated with the chance of achieving CSR (table 2). The effect of antibody specificity could not be estimated by multivariate analysis, being used as stratifying variable, probably acting as an effect modifier in the relationship between CSR and clinical variables. However, MuSKpositive patients had an increased risk of showing bulbar dysfunction (table e-3), suggesting that MuSK antibodies may have a causal role in determining disease severity.
MuSK antibodies define a clinically different subgroup of patients with MG that, in our series, was associated with a lower occurrence of CSR. Since treatments adopted were similar in the 3 subgroups, the observation of a different outcome underlines the impact of a different immunopathologic background in MuSK-positive MG. Indeed, MuSK antibodies belong to the immunoglobulin G4 subclass, do not bind complement, and cause disruption of the neuromuscular junction, and hence transmission, with a complex effect on several proteins involved in anchoring and stabilization of the AChR within the postsynaptic membrane. Experimental studies performed with MuSK antibodies showed depletion of postsynaptic MuSK leading to disassembly of the AChR scaffold, 20 and the disease has been induced in mice after immunization with MuSK. 21 However, the molecular basis of the different clinical manifestations and outcome associated with the presence of anti-AChR or anti-MuSK antibodies is still not understood. Nevertheless, the particular clinical aspects, positivity of anti-MuSK antibodies, and the lower chance of achieving CSR remain key points for the clinician in facing a patient with this form of MG. The low percentage of CSR suggests the need for more aggressive treatments from the onset, and the association of corticosteroids with immunosuppressive drugs should probably be considered as early as possible. This information has crucial implications for the management of MuSK-associated MG and planning therapeutic strategies and clinical trials in the future.
